Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. (Q44965337)

7 December 2017

Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. (English)

1 reference

7 December 2017

Amy G Shah

1

1 reference

PubMed ID

21526398

7 December 2017

Paula G Smith

series ordinal

2

1 reference

PubMed ID

21526398

7 December 2017

Richard K Sterling

series ordinal

3

1 reference

7 December 2017

28 April 2011

1 reference

Digestive Diseases and Sciences

7 December 2017

1 reference

7 December 2017

56

1 reference

7 December 2017

10

1 reference

7 December 2017

3038-3044

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-011-1710-2

7 December 2017

0 references

cites work

Hepatitis C in the HIV-Infected Person

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

The clinical spectrum of hepatitis C virus in HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1710-2

[Hepatitis C virus and human immunodeficiency virus co-infection]

21 January 2018

1 reference

12 December 2020

Assessing fibrosis without a liver biopsy: are we there yet?

1 reference

12 December 2020

Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients

1 reference

12 December 2020

A 21-year experience with major hemorrhage after percutaneous liver biopsy

1 reference

12 December 2020

Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients

1 reference

12 December 2020

Noninvasive prediction of fibrosis in patients with chronic hepatitis C

1 reference

12 December 2020

Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker

1 reference

12 December 2020

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

12 December 2020

Liver biopsy: Complications in 1000 inpatients and outpatients

1 reference

12 December 2020

10.1007/S10620-011-1710-2

Identifiers

DOI

1 reference

7 December 2017

1 reference

PubMed ID

21526398